SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This Phase IIa Randomized, Double-blind, Parallel Group, Placebo-controlled, multicenter
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Intravenous
Injection of SY-005（recombinant human annexin A5） in Sepsis Subjects. 96 patients will be
entered into the study and randomised in a 1:1:1:1 ratio to receive SY-005 2.5mg or SY-005
5mg or SY-005 10mg or placebo.